In patients with myelodysplastic syndromes (MDS), preexisting autoimmune disease is associated with a decreased risk for mortality, according to findings from a large population-based cohort analysis published in the journal Blood Advances. Among individuals with MDS, immune dysregulation has been shown to be a pathogenic driver of disease, with overly active immune responses promoting genetic…
A phase 3b, open-label study is set to assess the efficacy and safety of luspatercept administered at the maximum approved dose in low-risk patients with myelodysplastic syndromes (MDS) who require red blood cell transfusions. The study, set to start by mid-October, is not yet recruiting. The researchers are looking to enroll approximately 100 patients with…
Which of the statements below about the clinical features of myelodysplastic syndromes (MDS) are correct? Select one of the options for each question, then submit your answers to see how well you scored and how other test takers voted. Read more about MDS clinical features.
Researchers from the University of Texas MD Anderson Cancer Center, Houston, have conducted a comprehensive analysis of a large cohort of patients with myeloid neoplasms, including myelodysplastic syndromes (MDS), harboring DDX41 germline and somatic variants. Notably, most neoplasms (59%) displayed a normal karyotype. Additionally, the study revealed TP53 mutations in 16% of cases and ASXL1…
In patients with low-risk myelodysplastic syndromes (LR-MDS), transfusion dependence is a common challenge and can be associated with complications and decreased overall survival (OS), according to findings from a discrete-event simulation-based disease model presented at the Society of Hematologic Oncology 11th Annual Meeting and published in the journal Clinical Lymphoma, Myeloma & Leukemia. Recognizing that…
Particular drivers of clonal hematopoiesis are associated with a higher chance of developing myelodysplastic syndromes (MDS) and may yield significant changes in blood cell parameters, a study published in Nature Genetics suggested. The study included the medical records of 454,340 UK Biobank participants with clonal cytopenia of undetermined significance divided into 2 independent cohorts. Of all…
Researchers from France have identified a potential predictor of treatment outcomes in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) receiving azacitidine therapy. According to the study recently published in the British Journal of Haematology, half of the patients had deficient cytidine deaminase (CDA) activity (cutoff of 2 UA/mg)—an enzyme responsible for…
Several ongoing questions in the realm of myelodysplastic syndromes were discussed at the 11th Annual Meeting of the Society of Hematologic Oncology.
Luspatercept-aamt demonstrated superiority against epoetin alfa in the treatment of anemia in adults with ESA-naïve transfusion-dependent LR‑MDS.
Novel immunotherapeutic interventions have shown promise in harnessing the immune system’s capabilities to target malignant cells.
